Weight-Loss Segment Future Uncertain With PPA Actions, Ephedra Questions
This article was originally published in The Tan Sheet
Executive Summary
FDA actions discouraging the use of phenylpropanolamine-containing products will further accelerate the recent shift away from the OTC appetite suppressant ingredient toward ephedra supplements.